Amgen did a similar study around 2008 and found that denosumab halted erosions but did not protect the loss of cartilage so ultimately not enough joint protection when the study was extended.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.